Metastatic BRCA-Negative Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management
Update: 2025-09-23
Description
Featuring an interview with Prof Peter Schmid, including the following topics:
- Response to immunotherapy in breast cancer subtypes (0:00 )
- Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51 )
- Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03 )
- ADC structure and treatment-related adverse events (19:02 )
- Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06 )
- Novel ADCs and bispecific antibodies under investigation for mBC (28:30 )
- Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01 )
- Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06 )
Comments
In Channel